PIK3C2A
Basic information
Region (hg38): 11:17077730-17207986
Links
Phenotypes
GenCC
Source:
- oculocerebrodental syndrome (Supportive), mode of inheritance: AR
- oculocerebrodental syndrome (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Oculoskeletodental syndrome | AR | Audiologic/Otolaryngologic; Ophthalmologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; The condition can include secondary glaucoma, and awareness may allow prompt diagnosis and management | Audiologic/Otolaryngologic; Craniofacial; Endocrine; Musculoskeletal; Neurologic; Ophthalmologic | 31034465 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (11 variants)
- Oculocerebrodental syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PIK3C2A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 87 | 13 | 103 | |||
missense | 191 | 13 | 214 | |||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 6 | 16 | 2 | 24 | ||
non coding | 51 | 62 | ||||
Total | 12 | 2 | 198 | 151 | 31 |
Highest pathogenic variant AF is 0.0000131
Variants in PIK3C2A
This is a list of pathogenic ClinVar variants found in the PIK3C2A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-17089725-A-G | Oculocerebrodental syndrome | Benign (Sep 05, 2021) | ||
11-17089741-C-T | Likely benign (Jun 29, 2024) | |||
11-17089743-A-G | Likely benign (Dec 19, 2024) | |||
11-17089753-C-T | Likely benign (May 03, 2022) | |||
11-17089754-G-A | not specified | Uncertain significance (Oct 24, 2024) | ||
11-17089766-T-C | Uncertain significance (Apr 19, 2022) | |||
11-17089777-C-T | Likely benign (Oct 22, 2024) | |||
11-17089778-G-A | not specified | Uncertain significance (Jan 16, 2024) | ||
11-17089793-T-C | Likely benign (Aug 31, 2024) | |||
11-17089802-T-C | not specified | Uncertain significance (Jun 10, 2024) | ||
11-17089814-G-A | not specified | Uncertain significance (Apr 12, 2024) | ||
11-17089825-C-T | Likely benign (May 27, 2022) | |||
11-17089842-G-A | Uncertain significance (Oct 13, 2023) | |||
11-17089857-T-C | Uncertain significance (May 12, 2022) | |||
11-17089924-C-T | Likely benign (Apr 28, 2023) | |||
11-17091315-A-T | Benign (Jan 30, 2025) | |||
11-17091321-G-T | Likely benign (Jul 19, 2024) | |||
11-17091341-T-C | not specified | Uncertain significance (Sep 18, 2024) | ||
11-17091349-C-T | Likely benign (May 12, 2024) | |||
11-17091350-G-A | Uncertain significance (May 18, 2022) | |||
11-17091356-C-G | not specified | Uncertain significance (Jul 14, 2024) | ||
11-17091358-C-T | Likely benign (Mar 20, 2024) | |||
11-17091383-C-G | Uncertain significance (Jul 05, 2022) | |||
11-17091395-T-C | not specified | Uncertain significance (Sep 01, 2021) | ||
11-17091408-G-C | not specified | Uncertain significance (Aug 02, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PIK3C2A | protein_coding | protein_coding | ENST00000265970 | 32 | 130254 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0101 | 0.990 | 125696 | 0 | 50 | 125746 | 0.000199 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.30 | 749 | 856 | 0.875 | 0.0000422 | 11066 |
Missense in Polyphen | 233 | 351.06 | 0.66371 | 4629 | ||
Synonymous | 1.31 | 267 | 296 | 0.903 | 0.0000145 | 3174 |
Loss of Function | 6.59 | 23 | 90.7 | 0.254 | 0.00000512 | 1094 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000212 | 0.000212 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000927 | 0.0000924 |
European (Non-Finnish) | 0.000327 | 0.000325 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000133 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. Has a role in several intracellular trafficking events. Functions in insulin signaling and secretion. Required for translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane and glucose uptake in response to insulin- mediated RHOQ activation. Regulates insulin secretion through two different mechanisms: involved in glucose-induced insulin secretion downstream of insulin receptor in a pathway that involves AKT1 activation and TBC1D4/AS160 phosphorylation, and participates in the late step of insulin granule exocytosis probably in insulin granule fusion. Synthesizes PtdIns3P in response to insulin signaling. Functions in clathrin-coated endocytic vesicle formation and distribution. Regulates dynamin- independent endocytosis, probably by recruiting EEA1 to internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on large dense core vesicles. Participates in calcium induced contraction of vascular smooth muscle by regulating myosin light chain (MLC) phosphorylation through a mechanism involving Rho kinase-dependent phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role in the EGF signaling cascade. May be involved in mitosis and UV-induced damage response. Required for maintenance of normal renal structure and function by supporting normal podocyte function. {ECO:0000269|PubMed:10766823, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:12719431, ECO:0000269|PubMed:16215232, ECO:0000269|PubMed:21081650, ECO:0000269|PubMed:9337861}.;
- Pathway
- Inositol phosphate metabolism - Homo sapiens (human);Phosphatidylinositol signaling system - Homo sapiens (human);Proton Pump Inhibitor Pathway, Pharmacodynamics;Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics;Sorafenib Pharmacodynamics;VEGF Signaling Pathway;Phosphatidylinositol Phosphate Metabolism;Joubert syndrome;Signaling Pathways in Glioblastoma;Integrated Lung Cancer Pathway;Angiopoietin Like Protein 8 Regulatory Pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Microglia Pathogen Phagocytosis Pathway;Insulin Signaling;Regulation of Actin Cytoskeleton;DNA Damage Response (only ATM dependent);Golgi Associated Vesicle Biogenesis;Clathrin derived vesicle budding;trans-Golgi Network Vesicle Budding;Vesicle-mediated transport;Membrane Trafficking;Metabolism of lipids;Inositol phosphate metabolism;Metabolism;3-phosphoinositide biosynthesis;superpathway of inositol phosphate compounds;Phosphatidylinositol phosphate metabolism;Clathrin-mediated endocytosis;Synthesis of PIPs at the Golgi membrane;Synthesis of PIPs at the early endosome membrane;Synthesis of PIPs at the plasma membrane;Synthesis of PIPs at the late endosome membrane;PI Metabolism;Phospholipid metabolism;Integrins in angiogenesis
(Consensus)
Recessive Scores
- pRec
- 0.636
Intolerance Scores
- loftool
- 0.657
- rvis_EVS
- -1.48
- rvis_percentile_EVS
- 3.72
Haploinsufficiency Scores
- pHI
- 0.606
- hipred
- Y
- hipred_score
- 0.706
- ghis
- 0.649
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.988
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pik3c2a
- Phenotype
- growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; renal/urinary system phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype;
Zebrafish Information Network
- Gene name
- pik3c2a
- Affected structure
- intersegmental vessel
- Phenotype tag
- abnormal
- Phenotype quality
- process quality
Gene ontology
- Biological process
- phosphatidylinositol biosynthetic process;exocytosis;endocytosis;epidermal growth factor receptor signaling pathway;insulin receptor signaling pathway;phosphatidylinositol 3-kinase signaling;vascular smooth muscle contraction;cell migration;phosphatidylinositol-3-phosphate biosynthetic process;phosphatidylinositol phosphorylation;platelet-derived growth factor receptor signaling pathway;phosphatidylinositol-mediated signaling;clathrin coat assembly;membrane organization;positive regulation of cell migration involved in sprouting angiogenesis
- Cellular component
- nucleus;cytoplasm;Golgi apparatus;cytosol;plasma membrane;phosphatidylinositol 3-kinase complex;membrane;clathrin-coated vesicle;vesicle;extracellular exosome
- Molecular function
- ATP binding;1-phosphatidylinositol-3-kinase activity;phosphatidylinositol 3-kinase activity;1-phosphatidylinositol-4-phosphate 3-kinase activity;phosphatidylinositol binding